We demonstrated that our concept of modifying the pharmacophore of 99mTc-labeled GRPR antagonists at the Gln7-Trp8 results in improved tumor-to-organ ratios in the abdominal area at early time points. The gene discussed is GRPR; the disease is neoplasm.